Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

"Tirzepatide is currently FDA-approved for treating Type 2 diabetes, but it is being fast-tracked through the FDA to receive an indication for the treatment of obesity," Dr. Fatima Stanford of ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

The new tirzepatide trial, called SURMOUNT-1, included more than 2,500 volunteers who either met the medical definition of obesity, having a body mass index of 30 or above, or had a slightly lower ...